Likelihood to the new treatment of ovarian clear cell adenocarcinoma which classified individualization of the treatment

(1)mTOR-HIF-1通路的mTOR抑制剂Everolimus对其有抑制作用。Evelorimus可抑制HIF-1的细胞增殖能力，促进其降解途径(VHL)。对于该药物，有望通过mTOR-HIF-1途径在卵巢透明细胞腺癌中作为一种新的治疗药物。(2)体内治疗效果显示，埃博莫司+顺铂组比单用埃博利莫司组更具抗肿瘤作用。(3)作为透明细胞腺癌的治疗标志物，HIF-1的表达模式，p-mTOR的阳性率可能是有效的。

(1) The mTOR inhibitor (Everolimus) of the mTOR - HIF-1 pathway restrained it. evelorimus provided suppression of the cellular proliferative capacity and promotion of degradation pathway (VHL) of HIF-1. As for this drug, the likelihood as a new therapeutic drug through the mTOR - HIF-1 pathway in the ovarian clear cell adenocarcinoma was expected.(2) The effect of treatment in vivo showed antitumor effect more in Everolimus + CDDP group than an Everolimus single group.(3) As a treatment marker of the clear cell adenocarcinoma, expression patterns of HIF-1, a positive rate of p-mTOR may be effective.